Core Indications
• Severe obesity (BMI ≥35 kg/m’)
• Insulin-resistant type 2 diabetes (HOMA-IR ≥3.0)
Extended Indications
• Non-alcoholic steatohepatitis (NASH)
• Obesity-related chronic kidney disease (eGFR <60
mL/min/1.73m')
Features &Clinical Trial Data
1 Triple-Target Coverage:
• GLP-1R/GIPR:Dual regulation of glucose and appetite (24.2%weight loss at 48 weeks).
• GCGR:Activates hepatic metabolism,35%increase in basal metabolic rate(indirect calorimetry).
2 Technological Breakthrough:
• Buccal absorption technology achieves 15%bioavail- ability(7×higher than oral tablets).
• 60-second oral dissolution,50%shorter Tmax.
3 Phase ll Advantages:
• 48-week visceral fat reduction:31%(MRI)vs.18%for Tirzepatide.
• 45%reduction in glycemic variability(CGM data). 4 Safety Profile:
• Incidence of hepatic enzyme abnormalities<3%(under strict monitoring).
• Suitable for Prader-Willi syndrome obesity manage- ment.
• Room-temperature storage for 24 months,no cold chain required.
